Prime simplifies the cancer care pathway through innovative solutions that help manage complex conditions

July 17, 2026 publications 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview The 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview reflects Prime Therapeutics’ long‑standing...

Expert Clinical Insights Metastatic Melanoma MEDICATION INSIGHTS: Lifileucel (Amtagvi™) The U.S. Food and Drug Administration (FDA) approved lifileucel (Amtagvi™) in February 2024 through the...

NBC News: Patients weren't asked why they quit taking the weight loss drugs

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Prime Therapeutics’ analysis of claims data suggests patients require support to ensure continued use and lifestyle modification

Most patients taking drugs such as Wegovy for weight loss discontinue usage within a year, according to Prime Therapeutics

Millions of people desperate to lose weight want to take Wegovy or its sister drug Ozempic